FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. I	2. Issuer Name and Ticker or Trading Symbol PTC THERAPEUTICS, INC. [PTCT]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
SOUTHWELL DAVID P												CI J	l '	X Director 10% Owner					
(Last)	,	(First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 03/31/2023								Officer (give title Other (spe below) below)					
	C THERAPI RPORATE (EUTICS, INC.			4. 1	f Amer	ndmer	nt, Date	of Orig	inal Fi	led (Month/Da	ay/Year)	6. I Lin	ndividual or e)	Joint/Group	Filin	g (Check Ap	oplicable	
	u old II E				-										•		orting Perso	- 1	
(Street)														Form f Perso		e tha	n One Repo	orting	
PLAINF	IELD N.	J	07080		Ri	Rule 10b5-1(c) Transaction Indication													
(City) (State) (Zip)						X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - I	Non-Deri	vativ	e Sec	urit	ies A	cquire	ed, D	isposed o	f, or B	eneficia	lly Owned	d				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y			Execution Date,				s Acquired (A) or f (D) (Instr. 3, 4 and 5)		Securit Benefic	5. Amount of Securities Beneficially Owned Following		ownership m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership						
						(,		Code	v	Amount	(A) or (D)	Price	Transa	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
Common	Stock			03/31/2	2023				M ⁽¹⁾		2,571	A	\$18.01	. 13	3,071		D		
Common	Stock			03/31/2	2023				S ⁽¹⁾		2,571	D	\$50.047	5(2) 1(),500		D		
		٦	Table I								sposed of , converti			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed tion Date, n/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) o Disp of (I	posed D) tr. 3, 4	Expiration Date (Month/Day/Year)		ate	of Securities E Underlying S		8. Price of Derivative Security (Instr. 5) Securit Benefic Owned Following Reporter Transac (Instr. 4)		lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
											F		Amount or Number						
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	of Shares						
Stock Option (Right to Buy)	\$18.01	03/31/2023			M ⁽¹⁾			2,571	(3)	01/02/2028	Commor Stock	2,571	\$18.01	11,429	11,429			
Stock Option (Right to Buy)	\$51								(3)	01/02/2025	Commor Stock	12,000		12,000)	D		
Stock Option (Right to Buy)	\$30.86								(3)	01/03/2026	Commor Stock	12,000		12,000		D		
Stock Option (Right to Buy)	\$33.02								(3)	01/02/2029	Commor Stock	14,000		14,000)	D		
Stock Option (Right to Buy)	\$51.16								(3)	01/28/2030	Commor Stock	10,000		10,000)	D		
Stock Option (Right to Buy)	\$66.49								(3)	01/05/2031	Commor Stock	10,000		10,000)	D		
Stock Option (Right to Buy)	\$38.1								(3)	01/06/2032	Commor Stock	12,000		12,000)	D		
Stock Option (Right to	\$39.42								(4	-)	01/04/2033	Commor	10,000		10,000)	D		

Explanation of Responses:

- 1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023.
- 2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$50.00 to \$50.17 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 3. Currently exercisable.
- 4. This option was granted on January 5, 2023 and vests over one year in twelve equal monthly installments, commencing on February 5, 2023.

/s/ Avraham S. Adler,

Attorney-in-Fact

** Signature of Reporting Person Date

04/04/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.